Source: Fox News
Summary
The FDA has approved a new, higher-dose version of Wegovy (semaglutide) injection for weight loss and long-term weight loss maintenance in adult patients. The 7.2 mg dosage, called Wegovy HD, is triple the previous maximum dose of 2.4 mg. The approval was based on clinical data that found higher doses resulted in additional average weight reduction compared to previous dosing. The safety profile is consistent with the known side effects of semaglutide, which commonly include gastrointestinal reactions and skin sensitivity.
Our Reading
The advice sounds familiar.
The FDA’s approval of a higher-dose GLP-1 injection for weight loss is another example of the agency’s efforts to address national health priorities. The new dosage, Wegovy HD, is intended to provide adult patients with an additional therapeutic option for weight loss and weight reduction maintenance. However, the safety profile of the higher dose includes increased incidences of stomach- and skin-related side effects. As with any new treatment, patients should consult with their doctor for guidance on proper use.
It’s another chapter in the ongoing story of weight loss treatments, where the latest development is often just a new page in the same book.
Author: Evan Null
